WO2005030083A3 - Methodes et produits faisant intervenir de l'acide n-acyl-l-aspartique - Google Patents

Methodes et produits faisant intervenir de l'acide n-acyl-l-aspartique Download PDF

Info

Publication number
WO2005030083A3
WO2005030083A3 PCT/US2004/031443 US2004031443W WO2005030083A3 WO 2005030083 A3 WO2005030083 A3 WO 2005030083A3 US 2004031443 W US2004031443 W US 2004031443W WO 2005030083 A3 WO2005030083 A3 WO 2005030083A3
Authority
WO
WIPO (PCT)
Prior art keywords
products
methods
acyl
utilize
aspartic acid
Prior art date
Application number
PCT/US2004/031443
Other languages
English (en)
Other versions
WO2005030083A2 (fr
Inventor
David Bar-Or
Leonard T Rael
Original Assignee
Dmi Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dmi Biosciences Inc filed Critical Dmi Biosciences Inc
Priority to AU2004275821A priority Critical patent/AU2004275821A1/en
Priority to JP2006528239A priority patent/JP2007506767A/ja
Priority to EP04789036A priority patent/EP1663196A2/fr
Priority to CA002538352A priority patent/CA2538352A1/fr
Publication of WO2005030083A2 publication Critical patent/WO2005030083A2/fr
Publication of WO2005030083A3 publication Critical patent/WO2005030083A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
    • A61D7/00—Devices or methods for introducing solid, liquid, or gaseous remedies or other materials into or onto the bodies of animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne des méthodes et des produits thérapeutiques destinés au traitement de l'inflammation, de maladies et d'états inflammatoires, et de maladies et d'états prolifératifs. L'invention concerne également des méthodes et des produits permettant d'inhiber l'inflammation dans des cellules, des tissus et des organes excisés. L'invention concerne en outre des méthodes et des produits de soins buccaux destinés au traitement des tissus buccaux d'un animal. L'invention concerne enfin des méthodes et des produits de soins buccaux destinés au traitement de la peau d'un animal. L'ensemble de ces méthodes et produits font intervenir de l'acide N-acyl-L-aspartique ou un ester ou un sel acceptable sur le plan pharmaceutique associé.
PCT/US2004/031443 2003-09-25 2004-09-24 Methodes et produits faisant intervenir de l'acide n-acyl-l-aspartique WO2005030083A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2004275821A AU2004275821A1 (en) 2003-09-25 2004-09-24 Methods and products which utilize N-acyl-L-aspartic acid
JP2006528239A JP2007506767A (ja) 2003-09-25 2004-09-24 Ｎ−アシル−ｌ−アスパラギン酸を利用した方法および製造物
EP04789036A EP1663196A2 (fr) 2003-09-25 2004-09-24 Methodes et produits faisant intervenir de l'acide n-acyl-l-aspartique
CA002538352A CA2538352A1 (fr) 2003-09-25 2004-09-24 Methodes et produits faisant intervenir de l'acide n-acyl-l-aspartique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50632303P 2003-09-25 2003-09-25
US60/506,323 2003-09-25

Publications (2)

Publication Number Publication Date
WO2005030083A2 WO2005030083A2 (fr) 2005-04-07
WO2005030083A3 true WO2005030083A3 (fr) 2006-02-16

Family

ID=34393139

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/031443 WO2005030083A2 (fr) 2003-09-25 2004-09-24 Methodes et produits faisant intervenir de l'acide n-acyl-l-aspartique

Country Status (8)

Country Link
US (2) US20050192348A1 (fr)
EP (1) EP1663196A2 (fr)
JP (1) JP2007506767A (fr)
KR (1) KR20060088543A (fr)
CN (1) CN1886126A (fr)
AU (1) AU2004275821A1 (fr)
CA (1) CA2538352A1 (fr)
WO (1) WO2005030083A2 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
CA2502986C (fr) 2002-10-25 2011-08-23 Foamix Ltd. Mousse cosmetique et pharmaceutique
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
CN1886126A (zh) * 2003-09-25 2006-12-27 Dmi生物科学公司 利用n－酰基－l－天冬氨酸的方法和产品
AU2005302554A1 (en) * 2004-10-28 2006-05-11 Idexx Laboratories, Inc. Compositions for controlled delivery of pharmaceutically active compounds
US9566140B2 (en) 2005-04-27 2017-02-14 Dentovations Inc. Method and device for whitening teeth using sonochemistry
US7754679B2 (en) * 2005-11-16 2010-07-13 Idexx Laboratories, Inc. Pharmaceutical compositions for the administration of aptamers
CA2626368A1 (fr) * 2005-11-16 2007-05-24 Idexx Laboratories Inc. Compositions pharmaceutiques pour l'administration d'aptameres
US8114440B2 (en) * 2005-11-16 2012-02-14 Idexx Laboratories Inc. Pharmaceutical compositions for the administration of aptamers
WO2008045076A1 (fr) * 2006-10-12 2008-04-17 Dentovations Inc. Plateau moulable, système et procédé pour le blanchiment des dents
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
EP1932524A1 (fr) * 2006-12-13 2008-06-18 Ludwig-Maximilians-Universität München Préparations pharmaceutiques pour le traitement de maladies inflammatoires
US8298516B2 (en) * 2006-12-22 2012-10-30 Douglas Anderson Calculus dissolving dental composition and methods for using same
GB0625841D0 (en) * 2006-12-22 2007-02-07 Sinclair Pharmaceuticals Ltd Composition
US8828960B2 (en) * 2007-07-17 2014-09-09 Idexx Laboratories, Inc. Amino acid vitamin ester compositions for controlled delivery of pharmaceutically active compounds
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009069006A2 (fr) 2007-11-30 2009-06-04 Foamix Ltd. Peroxyde de benzoyle contenant de la mousse
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
WO2009090495A2 (fr) 2007-12-07 2009-07-23 Foamix Ltd. Vecteurs moussants siliconés à base d'huile et de liquide, et formulations
AU2009205314A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
CA2760186C (fr) 2009-04-28 2019-10-29 Foamix Ltd. Vehicule moussant et compositions pharmaceutiques comportant des solvants polaires aprotiques et leurs utilisations
CA2769677A1 (fr) 2009-07-29 2011-02-03 Foamix Ltd. Compositions hydro-alcooliques moussantes a base d'agents non tensioactifs non polymeres, mousses legeres, et leurs utilisations
WO2011013009A2 (fr) 2009-07-29 2011-02-03 Foamix Ltd. Compositions hydro-alcooliques moussantes non tensioactives, mousses légères, et leurs utilisations
CA2776366C (fr) 2009-10-02 2017-07-18 Foamix Ltd. Compositions moussantes sans eau et sans surfactant, mousses et gels friables, ainsi que leurs utilisations
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US8174881B2 (en) 2009-11-24 2012-05-08 Micron Technology, Inc. Techniques for reducing disturbance in a semiconductor device
AU2010365803B2 (en) 2010-12-20 2015-02-05 Colgate-Palmolive Company Gelatin encapsulated oral care composition containing hydrophilic active, hydrophobic structuring agent and oil carrier
EP2886163A1 (fr) * 2011-12-20 2015-06-24 Oriflame Research and Development Ltd. Composés présentant des activités anti-vieillissement
WO2017172476A1 (fr) * 2016-03-28 2017-10-05 The University Of Toledo Inhibiteurs puissants de l'aspartate n-acétyl-transférase pour le traitement de la maladie de canavan
MX2017011630A (es) 2016-09-08 2018-09-25 Foamix Pharmaceuticals Ltd Composiciones y metodos para tratar rosacea y acne.
CN116115596A (zh) * 2022-12-29 2023-05-16 甘肃大整行健康管理有限公司 N-乙酰-l-天门冬氨酸在制备预防或治疗肥胖药品或食品中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399570A (en) * 1992-04-13 1995-03-21 Cassella Aktiengesellschaft Aspartic acid derivatives, and their use for inhibiting platelete aggregation

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
AU527371B2 (en) * 1980-09-16 1983-03-03 Torii & Co., Ltd. Amidine
US4847283A (en) * 1983-01-10 1989-07-11 Harendza Harinxma Alfred J Ointment and method for treating skin lesions due to herpes virus
US4816449A (en) * 1984-08-09 1989-03-28 Immunetech Pharmaceuticals Immunotherapeutic anti-inflammatory peptide agents
US4798824A (en) * 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US4879283A (en) * 1985-10-03 1989-11-07 Wisconsin Alumni Research Foundation Solution for the preservation of organs
US5294431A (en) * 1987-01-30 1994-03-15 Colgate-Palmolive Co. Antibacterial antiplaque oral composition mouthwash or liquid dentifrice
US5180578A (en) * 1987-01-30 1993-01-19 Colgate-Palmolive Company Antibacterial antiplaque anticalculus oral composition
US5709873A (en) * 1988-02-26 1998-01-20 Niels Bukh A/S Method of treating conditions of teeth and their supporting tissue
US5032384A (en) * 1989-01-27 1991-07-16 Block Drug Company, Inc. Compositions and method for the treatment of disease
US5043183A (en) * 1989-09-13 1991-08-27 Cambridge Research Laboratories, Inc. Oral rinse and method for plaque removal
US5198220A (en) * 1989-11-17 1993-03-30 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5086069A (en) * 1990-02-05 1992-02-04 Rorer Pharmaceutical Corporation Anti-thrombotic peptide and pseudopeptide derivatives
ATE120951T1 (de) * 1990-10-25 1995-04-15 Boots Co Plc Mundwasser.
DE59203732D1 (de) * 1991-07-01 1995-10-26 Gergely Gerhard Lutsch- oder Kautablette.
JP2759895B2 (ja) * 1991-08-30 1998-05-28 サノフィ インターロイキン１βプロテアーゼをコードするＤＮＡ配列単離体
US5286479A (en) * 1991-12-10 1994-02-15 The Dow Chemical Company Oral compositions for suppressing mouth odors
US5298237A (en) * 1992-01-24 1994-03-29 The Trustees Of Columbia University In The City Of New York Gel composition for reduction of gingival inflammation and retardation of dental plaque
US5280038A (en) * 1992-03-13 1994-01-18 Virginia Commonwealth University Histidine as a protective agent in cardiac surgery and myocardial ischemic syndrome
US5785887A (en) * 1992-04-17 1998-07-28 Colgate-Palmolive Company Peroxygen bleach composition
US5855872A (en) * 1992-06-22 1999-01-05 Libin; Barry M. Compositions for treating herpes simplex virus infections
US5292527A (en) * 1992-07-02 1994-03-08 Bausch & Lomb Incorporated Non-alcoholic aqueous mouthwash
US5432178A (en) * 1992-09-18 1995-07-11 Ono Pharmaceutical Co., Ltd. Amidinophenol derivatives
US5242910A (en) * 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
BR9307332A (pt) * 1992-10-28 1999-06-01 Den Mat Corp Lavagem bucal antibacteriana
US5302375A (en) * 1992-11-19 1994-04-12 Colgate-Palmolive Company Oral composition having improved tooth whitening effect
US5863202A (en) * 1992-11-24 1999-01-26 Fontenot; Mark G. Device and method for treatment of dentition
US5980249A (en) * 1992-11-24 1999-11-09 Folh, Llc Method and device for treatment of dentition
US5405742A (en) * 1993-07-16 1995-04-11 Cyromedical Sciences, Inc. Solutions for tissue preservation and bloodless surgery and methods using same
US5476647A (en) * 1993-09-13 1995-12-19 American Dental Association Health Foundation Complex calcium and fluoride containing mouth rinses, dentifrices, and chewable tablets
FR2714369B1 (fr) * 1993-12-29 1996-01-26 Rhone Poulenc Chimie Silices abrasives pour compositions dentifrices.
WO1995027472A1 (fr) * 1994-04-07 1995-10-19 Richter Jon L Solution pour bains de bouche et procede de traitement de la bromopnee
CA2143037C (fr) * 1994-05-02 2002-04-30 Atma Chaudhari Rince-bouche exempt d'alcool
CN1127620A (zh) * 1994-07-10 1996-07-31 王海生 一种组合型高效牙膏
WO1996002275A1 (fr) * 1994-07-20 1996-02-01 Toyama Chemical Co., Ltd. Onguent buccal a liberation prolongee
US5660854A (en) * 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
WO1996030395A2 (fr) * 1995-03-31 1996-10-03 Takeda Chemical Industries, Ltd. Inhibiteur de la protease de cysteine
AU6734096A (en) * 1995-07-31 1997-02-26 Gerhard Gergely Chewing tablets with an effervescent action
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
DE69626297T2 (de) * 1995-09-25 2003-12-11 Robert Eric Montgomery Zahnbleichende zusammensetzungen
TW469135B (en) * 1995-10-03 2001-12-21 Chugai Pharmaceutical Co Ltd Chewable tablet
DE69724986T2 (de) * 1996-06-07 2004-07-15 Hercules Inc., Wilmington Zahnpasten enthaltend carboxymethylcellulose fluidisierte suspensionen
US5916548A (en) * 1996-09-04 1999-06-29 The Procter & Gamble Company Personal care compositions
US6200969B1 (en) * 1996-09-12 2001-03-13 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US5858332A (en) * 1997-01-10 1999-01-12 Ultradent Products, Inc. Dental bleaching compositions with high concentrations of hydrogen peroxide
US5879691A (en) * 1997-06-06 1999-03-09 The Procter & Gamble Company Delivery system for a tooth whitener using a strip of material having low flexural stiffness
US6026829A (en) * 1997-06-17 2000-02-22 Gillette Canada Inc. Dental floss containing encapsulating flavoring material
US5906811A (en) * 1997-06-27 1999-05-25 Thione International, Inc. Intra-oral antioxidant preparations
CA2239398C (fr) * 1997-07-10 2004-05-25 Robert V. Marcon Soie dentaire corrective
US5967155A (en) * 1997-07-10 1999-10-19 Marcon; Robert Victor Medicated dental floss
US6197331B1 (en) * 1997-07-24 2001-03-06 Perio Products Ltd. Pharmaceutical oral patch for controlled release of pharmaceutical agents in the oral cavity
AU753587B2 (en) * 1997-11-14 2002-10-24 Johnson & Johnson Consumer Companies, Inc. Highly flavored dental floss
US6228347B1 (en) * 1997-12-01 2001-05-08 Thione International, Inc. Antioxidant gel for gingival conditions
US6291514B1 (en) * 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
US6350438B1 (en) * 1998-02-27 2002-02-26 The Procter & Gamble Company Oral care compositions comprising chlorite and methods
US5876701A (en) * 1998-02-27 1999-03-02 Colgate Palmolive Company Striped toothpaste stable to color bleeding
US6251372B1 (en) * 1998-02-27 2001-06-26 The Procter & Gamble Company Oral care compositions comprising chlorite and methods
US6066673A (en) * 1998-03-12 2000-05-23 The Procter & Gamble Company Enzyme inhibitors
US5976507A (en) * 1998-06-04 1999-11-02 Colgate Palmolive Company Dentrifice composition containing encapsulated reactive ingredients
US6045780A (en) * 1998-06-22 2000-04-04 Shemberg Marketing Corporation Toothpaste composition
US6270790B1 (en) * 1998-08-18 2001-08-07 Mxneil-Ppc, Inc. Soft, convex shaped chewable tablets having reduced friability
US6060078A (en) * 1998-09-28 2000-05-09 Sae Han Pharm Co., Ltd. Chewable tablet and process for preparation thereof
US6358957B1 (en) * 1998-11-12 2002-03-19 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
US7026322B2 (en) * 1998-11-12 2006-04-11 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
US6296868B1 (en) * 1998-11-19 2001-10-02 Advanced Technology Pharmaceuticals Corporation Chewable tablets containing mannitol and aspartame
US6159485A (en) * 1999-01-08 2000-12-12 Yugenic Limited Partnership N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use
US6270781B1 (en) * 1999-01-08 2001-08-07 Maxim Pharmaceuticals, Inc. Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors
US6808716B2 (en) * 1999-01-08 2004-10-26 Ruey J. Yu N-acetylamino acids, related N-acetyl compounds and their topical use
US7288545B2 (en) * 2000-05-09 2007-10-30 Angiorx Corporation Piperazinedione compounds
EP1282609B1 (fr) * 2000-05-09 2008-12-17 AngioRx Corporation Composes de piperazinedione
EP1311269B1 (fr) * 2000-08-04 2012-02-29 DMI Biosciences, Inc. Methode d'utilisation de dicetopiperazines et composition contenant ces substances
US6419906B1 (en) * 2001-03-12 2002-07-16 Colgate Palmolive Company Strip for whitening tooth surfaces
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
CN1886126A (zh) * 2003-09-25 2006-12-27 Dmi生物科学公司 利用n－酰基－l－天冬氨酸的方法和产品

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399570A (en) * 1992-04-13 1995-03-21 Cassella Aktiengesellschaft Aspartic acid derivatives, and their use for inhibiting platelete aggregation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"The Merck Index, 12th edition.", 1996, pages: 142, XP008059423 *

Also Published As

Publication number Publication date
US20050192348A1 (en) 2005-09-01
JP2007506767A (ja) 2007-03-22
CA2538352A1 (fr) 2005-04-07
AU2004275821A1 (en) 2005-04-07
CN1886126A (zh) 2006-12-27
WO2005030083A2 (fr) 2005-04-07
US20080167376A1 (en) 2008-07-10
EP1663196A2 (fr) 2006-06-07
KR20060088543A (ko) 2006-08-04

Similar Documents

Publication Publication Date Title
WO2005030083A3 (fr) Methodes et produits faisant intervenir de l'acide n-acyl-l-aspartique
IL291162A (en) Isolated human rpe cells and their use for the treatment of retinal degenerative diseases
WO2003096990A3 (fr) Cages proteiques pour l'administration d'agents therapeutiques et d'imagerie medicale
WO2005062881A3 (fr) Therapie genique faisant intervenir des vecteurs de transposon
EP1581169A4 (fr) Compositions et procedes de traitement des maladies liees aux cellules k naturelles
WO2003099771A3 (fr) Derives de diaryle-uree utilises pour le traitement des maladies dependant des proteines kinases
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
ZA200707934B (en) Thereapeutic formulations for the treatment of beta-amyloid related diseases
IL178142A0 (en) Methods of using and compositions comprising immunomodulatory compounos for the treatment and management of skin diseases or disorders
EP1571968A3 (fr) Compositions et methodes permettant de diagnostiquer et de traiter une tumeur
WO2003041686A3 (fr) Traitement ameliore de maladies topiques
WO2006003488A3 (fr) Annexines, derives de ces dernieres, variantes d'annexines-cys et utilisations therapeutiques et diagnostiques de ces dernieres
EP1572091A3 (fr) Compositions et methodes de diagnostic et de traitement de tumeurs
AU2003278775A8 (en) Porifera-based therapeutic compositions for treating and preventing skin diseases
WO2003057160A8 (fr) Compositions et methodes de diagnostic et de traitement d'une tumeur
HK1089380A1 (en) Treatment of bacterial diseases of the respiratory organs by locally applying fluoroquinolones
WO2004031129A3 (fr) Nouveaux composes destines au traitement des maladies auto-immunes, des maladies immuno-allergiques et des rejets en cas de greffes d'organes ou de tissus
EP1636160A4 (fr) Nouveaux agents therapeutiques permettant de traiter le cancer, les maladies metaboliques et les affections cutanees
WO2005003154A8 (fr) Compositions et methodes de diagnostic et de traitement de tumeur
PL371281A1 (en) Methods and compositions for the treatment of eye diseases
WO2004033660A3 (fr) Profilage d'expression genique a partir d'echantillons de type ffpe, fixes par formaline (ff) et imbriques en parafine (pe)
WO2007025229A3 (fr) Compositions et utilisations contre hsp27
AU2003237792A1 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004100893A3 (fr) Methodes de traitement d'affections inflammatoires a l'aide de ct-3 ou de ses analogues
AU2002364501A1 (en) Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480034908.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2538352

Country of ref document: CA

Ref document number: 545854

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004789036

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020067005801

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006528239

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004275821

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004275821

Country of ref document: AU

Date of ref document: 20040924

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004275821

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004789036

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067005801

Country of ref document: KR